Coegin Pharma rapporterar positiva top-line data från COAK-studien, en klinisk fas I/II studie med AVX001 inom aktinisk keratos
Coegin Pharma, a Nordic biotechnology company that, with unique technologies and competencies, develops novel treatments in cancer and inflammatory-driven diseases today reports positive top-line data from its COAK study - a clinical Phase I/II trial in which the safety and tolerability of AVX001 was evaluated in 60 patients with actinic keratosis. The findings demonstrated that two different doses of AVX001 (1% and 3%) are safe and well tolerated in treatment of patients with actinic keratosis. While the study was not designed to draw definite conclusions on efficacy, the findings indicate a clear tendency to efficacy and a potential for AVX001 to become a future treatment option for patients with actinic keratosis. Based on these results, additional in-depth analyses of the findings from the study are ongoing in parallel with the evaluation and planning of the continued clinical development of AVX001.
Coegin Pharma reports positive top-line results from the COAK study, a clinical Phase I/II trial with AVX001 in actinic keratosis
Coegin Pharma, a Nordic biotechnology company that, with unique technologies and competencies, develops novel treatments in cancer and inflammatory-driven diseases today reports positive top-line data from its COAK study - a clinical Phase I/II trial in which the safety and tolerability of AVX001 was evaluated in 60 patients with actinic keratosis. The findings demonstrated that two different doses of AVX001 (1% and 3%) are safe and well tolerated in treatment of patients with actinic keratosis. While the study was not designed to draw definite conclusions on efficacy, the findings indicate a clear tendency to efficacy and a potential for AVX001 to become a future treatment option for patients with actinic keratosis. Based on these results, additional in-depth analyses of the findings from the study are ongoing in parallel with the evaluation and planning of the continued clinical development of AVX001.
Lars Bukhave Rasmussen tillträder som ny CFO i Coegin Pharma
Sista patientbesöket i Coegin Pharmas COAK-studie är nu genomfört
Coegin Pharma AB (publ) publicerar bokslutskommuniké för perioden januari - december 2021
Coegin Pharma beslutar om emission av fusionsvederlag
BioStock publicerar artikel om Coegin Pharmas uppnådda milstolpar under 2021 och förväntningar under 2022
Coegin Pharma AB
Webbplats:
coeginpharma.com/
Bransch: Sjukvård
Kortnamn: COEGIN
Marknadsplats: Nordic SME
Senaste rapporten:
Årsredovisning 2021
Nästa evenemang:
2022-08-25 Delårsrapport Q2 2022
Kurs
Kurs:
Marknadsvärde: